316 related articles for article (PubMed ID: 20216161)
1. Acute pulmonary hypertension in infants and children: cGMP-related drugs.
Fraisse A; Wessel DL
Pediatr Crit Care Med; 2010 Mar; 11(2 Suppl):S37-40. PubMed ID: 20216161
[TBL] [Abstract][Full Text] [Related]
2. Use of sildenafil to facilitate weaning from inhaled nitric oxide in children with pulmonary hypertension following surgery for congenital heart disease.
Lee JE; Hillier SC; Knoderer CA
J Intensive Care Med; 2008; 23(5):329-34. PubMed ID: 18701525
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary hypertension: inhaled nitric oxide, sildenafil and natriuretic peptides.
Steiner MK; Preston IR; Klinger JR; Hill NS
Curr Opin Pharmacol; 2005 Jun; 5(3):245-50. PubMed ID: 15907910
[TBL] [Abstract][Full Text] [Related]
4. Intravenous sildenafil is a potent pulmonary vasodilator in children with congenital heart disease.
Schulze-Neick I; Hartenstein P; Li J; Stiller B; Nagdyman N; Hübler M; Butrous G; Petros A; Lange P; Redington AN
Circulation; 2003 Sep; 108 Suppl 1():II167-73. PubMed ID: 12970227
[TBL] [Abstract][Full Text] [Related]
5. Pulmonary vasodilator therapy in the NICU: inhaled nitric oxide, sildenafil, and other pulmonary vasodilating agents.
Porta NF; Steinhorn RH
Clin Perinatol; 2012 Mar; 39(1):149-64. PubMed ID: 22341543
[TBL] [Abstract][Full Text] [Related]
6. Sildenafil improves the beneficial haemodynamic effects of intravenous nitrite infusion during acute pulmonary embolism.
Dias-Junior CA; Montenegro MF; Florencio BC; Tanus-Santos JE
Basic Clin Pharmacol Toxicol; 2008 Oct; 103(4):374-9. PubMed ID: 18834358
[TBL] [Abstract][Full Text] [Related]
7. Sarcoidosis-associated pulmonary hypertension: acute vasoresponsiveness to inhaled nitric oxide and the relation to long-term effect of sildenafil.
Milman N; Svendsen CB; Iversen M; Videbaek R; Carlsen J
Clin Respir J; 2009 Oct; 3(4):207-13. PubMed ID: 20298406
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic and hemodynamic responses to oral sildenafil during invasive testing in children with pulmonary hypertension.
Apitz C; Reyes JT; Holtby H; Humpl T; Redington AN
J Am Coll Cardiol; 2010 Apr; 55(14):1456-62. PubMed ID: 20359596
[TBL] [Abstract][Full Text] [Related]
9. Outcome of oral sildenafil therapy on persistent pulmonary hypertension of the newborn at Queen Sirikit National Institute of Child Health.
Khorana M; Yookaseam T; Layangool T; Kanjanapattanakul W; Paradeevisut H
J Med Assoc Thai; 2011 Aug; 94 Suppl 3():S64-73. PubMed ID: 22043756
[TBL] [Abstract][Full Text] [Related]
10. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
11. Cardiovascular effects of sildenafil in neonates and infants with congenital diaphragmatic hernia and pulmonary hypertension.
Noori S; Friedlich P; Wong P; Garingo A; Seri I
Neonatology; 2007; 91(2):92-100. PubMed ID: 17344658
[TBL] [Abstract][Full Text] [Related]
12. [Sildenafil in neonate pulmonary hypertension: the opinion of neonatology physician].
Condò V; Colnaghi MR; Mosca E
Pediatr Med Chir; 2008; 30(3):156-8. PubMed ID: 19024860
[No Abstract] [Full Text] [Related]
13. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of pulmonary arterial hypertension: phosphodiesterase-5 inhibitors].
Ghofrani HA; Grimminger F
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S311-4. PubMed ID: 17139594
[TBL] [Abstract][Full Text] [Related]
15. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children.
Namachivayam P; Theilen U; Butt WW; Cooper SM; Penny DJ; Shekerdemian LS
Am J Respir Crit Care Med; 2006 Nov; 174(9):1042-7. PubMed ID: 16917115
[TBL] [Abstract][Full Text] [Related]
16. Acute and chronic effects of sildenafil in patients with pulmonary arterial hypertension.
Preston IR; Klinger JR; Houtches J; Nelson D; Farber HW; Hill NS
Respir Med; 2005 Dec; 99(12):1501-10. PubMed ID: 15890512
[TBL] [Abstract][Full Text] [Related]
17. Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension.
Ghofrani HA; Pepke-Zaba J; Barbera JA; Channick R; Keogh AM; Gomez-Sanchez MA; Kneussl M; Grimminger F
J Am Coll Cardiol; 2004 Jun; 43(12 Suppl S):68S-72S. PubMed ID: 15194181
[TBL] [Abstract][Full Text] [Related]
18. Oral sildenafil reduces pulmonary hypertension after cardiac surgery.
Trachte AL; Lobato EB; Urdaneta F; Hess PJ; Klodell CT; Martin TD; Staples ED; Beaver TM
Ann Thorac Surg; 2005 Jan; 79(1):194-7; discussion 194-7. PubMed ID: 15620942
[TBL] [Abstract][Full Text] [Related]
19. Management of pulmonary arterial hypertension in the neonatal unit.
Krishnan U
Cardiol Rev; 2010; 18(2):73-5. PubMed ID: 20160532
[TBL] [Abstract][Full Text] [Related]
20. [Clinical use of phosphodiesterase-5 inhibitors in cardiopulmonary diseases: from experimental evidence to clinical application].
Guazzi M; Vicenzi M; Samaja M
G Ital Cardiol (Rome); 2009; 10(11-12):725-37. PubMed ID: 20101899
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
